name: Acetaminophen- and dextromethorphan- and promethazine-containing product


name: Acetaminophen- and dextromethorphan- and promethazine-containing product in oral dose form


name: Surgical procedure on outlet of urinary bladder


name: Insertion of dental bridge with resin and noble metal pontic onto tooth


name: Insertion of dental bridge with porcelain fused to base metal pontic onto tooth


name: Insertion of dental bridge with base metal pontic onto tooth


name: Insertion of dental bridge with porcelain fused to noble metal pontic onto tooth


name: Arterial bypass graft of upper limb artery using arterial graft


name: Cystodiathermy of lesion of urinary bladder


name: Occult blood detected in feces by immunoassay


name: Insertion of dental bridge with noble metal pontic onto tooth


name: Restoration of tooth with resin and noble metal crown


name: Live attenuated Rubella virus antigen only vaccine product


name: Pediatric acellular Bordetella pertussis and Clostridium tetani toxoid and Corynebacterium diphtheriae toxoid antigens only vaccine product


name: Restoration of tooth with full coverage noble metal crown


name: Cannabis-filled electronic cigarette user


name: Neonatal resuscitation using T-piece resuscitator


name: Family history of adenomatous polyp of colon


name: Laparoscopic repair of hernia using surgical mesh


name: Transurethral operation on urinary bladder


name: Empagliflozin and metformin only product in oral dose form


name: Miller classification for gingival recession class I


name: Miller classification for gingival recession class II


name: Miller classification for gingival recession class III


name: Miller classification for gingival recession class IV


name: Peanut+hazelnut+Brazil nut+almond+coconut specific IgE antibody measurement


name: Pecan nut+cashew nut+ pistachio+walnut specific IgE antibody measurement


name: Custom made resurfacing long bone prosthesis


name: Vena cava hemodynamic monitoring system balloon catheter


name: Assessment of residence and accommodation circumstances


name: Verification of activity of daily living needs


name: International normalized ratio time in therapeutic range expressed as percentage


name: Blood and marrow transplantation service


name: Assessment using Childhood Asthma Control Test


name: Referral to mental health service declined


name: Royal College of Physicians NEWS2 (National Early Warning Score 2)


name: Laparoscopic procedure with conversion to open approach


name: Assesses patient and procedure related risk factors for VTE


name: Assesses presence of prosthetics, implants, corrective devices or metal jewelry


name: Assesses risk factors for retained surgical items


name: Assesses risk factors and contraindications for pneumatic tourniquet use


name: Evaluates verification process for correct patient, procedure, site, side, and level


name: Evaluates status of indwelling catheters, drainage tubes, and surgical drains


name: Manages human cells, tissues and organs for implantation/transplantation


name: Manages the counting of surgical soft goods, sharps, miscellaneous items, and instruments.


name: Provides ethical care by protecting the patient's rights


name: Provides patient advocacy to protect the patient from incompetent, unethical, or illegal practices


name: Administers prescribed electrolyte therapy


name: Administers prescribed antibiotic therapy


name: Administers prescribed immunizing agents


name: Administers prescribed blood products or blood recovery


name: Administers care to indwelling catheters, drainage tubes, and surgical drains


name: Implements Immediate Use Steam Sterilization (IUSS)


name: Manages autologous tissues for reimplantation or auto transplantation


name: Implements complementary care nursing interventions


name: Provides perioperative teaching and support to patient or designated support person


name: Free from harm related to unintentional contamination of the sterile field and wound


name: Peripheral tissue perfusion is maintained at or improved from baseline levels


name: Free from injury related to an incorrect procedure performed


name: Demonstrates knowledge of the operative or invasive procedure and expected results


name: At increased risk for venous thromboembolism


name: Deficient knowledge of nutritional regimen


name: Deficient knowledge of psychosocial response to procedure


name: Medical Dictionary for Regulatory Activities Terminology (MedDRA), Finnish Edition


name: TITANIUM DIOXIDE 2.88 mg in 100 mg / ZINC OXIDE 6.8 mg in 100 mg TOPICAL LOTION [NORWEX Protect Prevent Mineral Facial Sunscreen Broad Spectrum SPF30]


name: ZINC OXIDE 12 mg in 100 mg TOPICAL CREAM [Bubble Solar Mate Daily Mineral Sunscreen SPF 40]


name: AVOBENZONE 2 mg in 100 mg / HOMOSALATE 6 mg in 100 mg / OCTOCRYLENE 1.6 mg in 100 mg / OCTISALATE 5 mg in 100 mg TOPICAL LOTION [NARS Radiance Primer Broad Spectrum SPF 35 Sunscreen]


name: AVOBENZONE 2 mg in 100 mg / HOMOSALATE 9 mg in 100 mg / OCTOCRYLENE 2 mg in 100 mg / OCTISALATE 4.5 mg in 100 mg TOPICAL SPRAY [Morphe SPF 30 Broad Spectrum Sunsetter Setting]


name: AVOBENZONE 3 mg in 100 mg / HOMOSALATE 10 mg in 100 mg / OCTOCRYLENE 4 mg in 100 mg / OCTISALATE 5 mg in 100 mg TOPICAL LOTION [KOPARI Sun Shield Soft Glow Daily Face SPF30]


name: AVOBENZONE 3 mg in 100 mg / HOMOSALATE 10 mg in 100 mg / OCTOCRYLENE 4 mg in 100 mg / OCTISALATE 5 mg in 100 mg TOPICAL SPRAY [KOPARI Sun Shield Soft Glow Daily Face SPF30]


name: AVOBENZONE 3 mg in 100 mg / HOMOSALATE 6 mg in 100 mg / OCTISALATE 5 mg in 100 mg TOPICAL LOTION [GLOSSIER INVISIBLE SHIELD DAILY SUNSCREEN BROAD SPECTRUM SPF 35]


name: AVOBENZONE 3 mg in 100 mg / HOMOSALATE 9.5 mg in 100 mg / OCTISALATE 5 mg in 100 mg TOPICAL LOTION [NEORA Invisibloc Sunscreen Gel Broad Spectrum SPF40]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 90 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 50 mg in 1 mL TOPICAL CREAM [CHEVOURI Brightening Serum Broad Spectrum SPF-40]


name: Avobenzone 20 mg in 1 g / Octisalate 50 mg in 1 g / Octocrylene 80 mg in 1 g TOPICAL CREAM [Lancome Paris Absolue Premium Bx Replenishing Rejuvenating Broad Spectrum SPF 15 Day]


name: OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL GEL [Zealios SPF LipGuard]


name: OCTINOXATE 1.5 g in 30 g / TITANIUM DIOXIDE 0.51 g in 30 g TOPICAL CREAM [No7 Lift and Luminate Triple Action Serum Foundation Sunscreen Broad Spectrum SPF 15 Warm Beige]


name: ZINC OXIDE 14.4 mg in 100 mg TOPICAL LOTION [KOPARI Antioxidant Face Shield Mineral SPF 30]


name: ZINC OXIDE 21 g in 100 g TOPICAL CREAM [Best Skin Days BS SPF 30]


name: La Prairie Concealer-Foundation Sunscreen SPF 15 SUNSET BEIGE KIT


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 120 mg in 1 mL / OCTISALATE 50 mg in 1 mL TOPICAL LOTION [Sheer Touch Sunscreen SPF 55]


name: Aluminum Sesquichlorohydrate 0.15 kg in 1 kg TOPICAL Lotion [Carpe Antiperspirant Underarm]


name: HOMOSALATE 10 g in 50 mL / AVOBENZONE 3 g in 50 mL / OCTISALATE 5 g in 50 mL TOPICAL LOTION [Naturium Dew Glow Tinted Moisturizer SPF50-deep]


name: HOMOSALATE 10 g in 50 mL / AVOBENZONE 3 g in 50 mL / OCTISALATE 5 g in 50 mL TOPICAL LOTION [Naturium Dew Glow Tinted Moisturizer SPF50]


name: OCTINOXATE 60 mg in 1 mL TOPICAL CREAM [Skin CaviarConcealer-Foundation Sunscreen SPF 15 SUNSET BEIGE]


name: HOMOSALATE 100 mg in 1 mL / OCTOCRYLENE 50 mg in 1 mL / OCTISALATE 40 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL LOTION [solful face sunlotion]


name: OCTISALATE 5 mg in 100 mg / AVOBENZONE 2.5 mg in 100 mg / HOMOSALATE 10 mg in 100 mg TOPICAL STICK [Bath and Body Works SPF20 Coconut Lip Balm]


name: TITANIUM DIOXIDE 2.37 g in 100 g / ZINC OXIDE 13.35 g in 100 g TOPICAL LOTION [Sheer Tint Mineral Sunscreen Broad Spectrum SPF 50 - Light/Medium Shade]


name: TITANIUM DIOXIDE 2.37 g in 100 g / ZINC OXIDE 13.35 g in 100 g TOPICAL LOTION [Sheer Tint Mineral Sunscreen Broad Spectrum SPF 50 - Medium/Deep Shade]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 70 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 70 mg in 1 mL TOPICAL LOTION [IT COSMETICS HELLO SUNSHINE INVISIBLE HYDRATING SERUM BROAD SPECTRUM SPF 50 SUNSCREEN]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 70 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 70 mg in 1 mL TOPICAL LOTION [La Roche Posay Laboratoire Dermatologique Anthelios UV Hydra Daily Invisible Broad Spectrum SPF 50 Sunscreen]


name: HOMOSALATE 9 g in 100 g / AVOBENZONE 3 g in 100 g / OCTOCRYLENE 6 g in 100 g / OCTISALATE 4.5 g in 100 g TOPICAL AEROSOL, SPRAY [BANANA BOAT]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTINOXATE 75 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 100 mg in 1 mL TOPICAL CREAM [CLARINS BROAD SPECTRUM SPF 50 Sunscreen Body]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 27 mg in 1 mL / OXYBENZONE 60 mg in 1 mL TOPICAL CREAM [CLARINS BROAD SPECTRUM SPF 50 Dry Touch Facial Sunscreen]


name: AVOBENZONE 30 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 90 mg in 1 mL TOPICAL OIL [Bali Body Watermelon Tanning Oil SPF 15]


name: OCTISALATE 5 g in 100 g / HOMOSALATE 10 g in 100 g / AVOBENZONE 3 g in 100 g / OCTOCRYLENE 10 g in 100 g TOPICAL CREAM [Drs. pharmacy sunscreen SPF 70]


name: OCTISALATE 5 g in 100 g / HOMOSALATE 10 g in 100 g / AVOBENZONE 3 g in 100 g / OCTOCRYLENE 10 g in 100 g TOPICAL LOTION [Drs. pharmacy sunscreen SPF 30]


name: OCTOCRYLENE 7.5 g in 100 g / AVOBENZONE 3 g in 100 g / HOMOSALATE 9 g in 100 g TOPICAL LOTION [BANANA BOAT]


name: TITANIUM DIOXIDE 45.5 mg in 1 mL / ZINC OXIDE 35 mg in 1 mL TOPICAL LIQUID [sugar rush skin treat poreless tinted moisturizer Broad Spectrum SPF 20 Sunscreen fair-light]


name: ENSULIZOLE 2.384 g in 100 mL / OCTISALATE 5.96 g in 100 mL / OCTOCRYLENE 5.96 g in 100 mL / ZINC OXIDE 23.1248 g in 100 mL TOPICAL EMULSION [cle de peau BEAUTE UV PROTECTIVE FOR BODY N]


name: ZINC OXIDE 10.2 g in 100 g / TITANIUM DIOXIDE 1 g in 100 g TOPICAL STICK [LiProtect SPF 35]


name: ZINC OXIDE 170 mg in 1 mL TOPICAL CREAM [Radiant Shield Broad spectrum SPF 40 Tinted Mineral Sunscreen]


name: ZINC OXIDE 173 mg in 1 mL TOPICAL CREAM [Circadia Circa-Shield Mineral Sunscreen SPF 30]


name: CHLOROXYLENOL 0.2 g in 100 g CUTANEOUS LIQUID [JuniperCleanDishSoap Apple]


name: ZINC OXIDE 15 g in 100 mL TOPICAL LOTION [NUDESCREEN BLUSH TINT SPF 30 - PEACHES N SOL]


name: Pedialyte with Immune Support, oral solution


name: Formula, Infant Oral Powder for Suspension [UCD Anamix Infant]


name: Medical Food Oral Suspension [ProSource Cup]


name: salicylic acid / selenium sulfide / zinc pyrithione


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 70 mg in 1 mL TOPICAL LOTION [Garnier SkinActive Clearly Brighter AntiSun Damage Daily Moisturizer Broad Spectrum SPF 30 Sunscreen]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 73 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 100 mg in 1 mL TOPICAL LOTION [NYX Professional Makeup Blurscreen Primer Broad Spectrum SPF 30 Sunscreen]


name: TITANIUM DIOXIDE 4.5 g in 100 g / ZINC OXIDE 4 g in 100 g TOPICAL LOTION [Coral Isle SPF 50 Mineral Sunscreen]


name: TRACH TUBE,SZ 7 BIVONA SMITHS #60AFHXL70


name: CATHETER,INTERMITTENT COUDE 16FR CURE #ULTRAM16C


name: BAG,ENTERAL DRAINAGE SET ENFIT #DBISO-100


name: CATHETER,INTERMITTENT VAPRO PLUS 12FR H#71122


name: DRESSING,ECLYPSE BORDER SUPER ABSORBENT #CR4299


name: STOMA CAPTURE CARTRIDGE STOMAGIENICS #12014


name: OCTINOXATE 7.5 g in 100 g / AVOBENZONE 2 g in 100 g / OCTISALATE 5 g in 100 g TOPICAL CREAM [RICH GIRL HAND SPF 25]


name: OCTOCRYLENE 70 mg in 1 mL / AVOBENZONE 30 mg in 1 mL / HOMOSALATE 70 mg in 1 mL / OCTISALATE 45 mg in 1 mL TOPICAL CREAM [GINZING SPF 30 DAILY MOISTURIZER]


name: diclofenac sodium/capsaicin 2 %-0.025 % TOPICAL COMBINATION PACKAGE (GRAM)


name: diluent no.1 for live virus vaccines (sterile water) SUBCUT SYRINGE (ML)


name: hyaluronate sodium, stabilized 60 mg/3 mL IMPLANT GEL IMPLANT IN SYRINGE (ML)


name: pediatric nutrition with iron, lactose free 5 gram-180 kcal/36 gram ORAL POWDER (GRAM)


name: pediatric nutrition with iron, lactose free 5 gram-210 kcal/45 gram ORAL POWDER (GRAM)


name: Kate Farms Pediatric Blended Meals 1.0 Cal/mL Nutrition (Banana & Blue)


name: Kate Farms Pediatric Blended Meals 1.0 Cal/mL Nutrition (Squash & Carrot)


name: Clever Choice Comfort EZ PRO 30G 5/16 inch Insulin Pen Needle


name: Clever Choice Comfort EZ PRO 31G 3/16 inch Insulin Pen Needle


name: Clever Choice Comfort EZ PRO 31G 5/32 inch Insulin Pen Needle


name: POLIDENT Overnight Whitening Antibacterial Denture Cleanser 4-in-1 Tablet


name: PuraPly Antimicrobial Wound Matrix (2.05x3.05cm)


name: PuraPly Antimicrobial Wound Matrix (3.76cm x 3.76cm)


name: ZINC OXIDE 10.49 g in 100 g / TITANIUM DIOXIDE 3.13 g in 100 g TOPICAL LOTION [Prime Time Daily Protecting Primer SPF 30]


name: ZINC OXIDE 175 mg in 1 mL TOPICAL CREAM [Valmont Daily Veil. Moisturizing Face Fluid Mineral Sunscreen]


name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 15.2 g in 100 g TOPICAL STICK [Degree]


name: ZINC OXIDE 24.08 g in 100 g TOPICAL AEROSOL, SPRAY [Coppertone Pure and Simple Baby Sunscreen SPF 50]


name: CLENBUTEROL HYDROCHLORIDE 100 g in 100 g NOT APPLICABLE POWDER


name: FIROCOXIB 1 kg in 1 kg NOT APPLICABLE POWDER


name: magnesium salicylate, combinations excl. psycholeptics


name: perindopril, bisoprolol, amlodipine and indapamide


name: sodium phenylbutyrate and ursodoxicoltaurine


name: Combinations of monoclonal antibodies and antibody drug conjugates


name: Dihydroorotate dehydrogenase (DHODH) inhibitors


name: Sphingosine-1-phosphate (S1P) receptor modulators


name: OCTINOXATE 1.28 g in 17 g / AVOBENZONE 0.51 g in 17 g / OCTISALATE 0.85 g in 17 g / OXYBENZONE 1.02 g in 17 g / OCTOCRYLENE 0.85 g in 17 g TOPICAL STICK [CANNON BALM 140]


name: AVOBENZONE 3 g in 100 g / HOMOSALATE 9 g in 100 g / OCTOCRYLENE 9 g in 100 g / OCTISALATE 4.5 g in 100 g TOPICAL AEROSOL, SPRAY [Coppertone UV Protect Sunscreen SPF 50]


name: HOMOSALATE 30 mg in 1 mL / OCTINOXATE 60 mg in 1 mL / OXYBENZONE 30 mg in 1 mL TOPICAL CREAM [Dragons Blood SPF15]


name: OCTISALATE 4.5 g in 100 g / OCTOCRYLENE 9 g in 100 g / HOMOSALATE 9 g in 100 g / AVOBENZONE 3 g in 100 g TOPICAL LOTION [Coppertone 5X UV Protect Face Sunscreen]


name: AVOBENZONE 30 mg in 1 g / HOMOSALATE 73.4 mg in 1 g / OCTOCRYLENE 50 mg in 1 g / OCTISALATE 50 mg in 1 g TOPICAL STICK [Aruba Aloe broad spectrum SPF 15 Lip sunscreen and Moisturizer]


name: ZINC OXIDE 8.5 g in 100 g / TITANIUM DIOXIDE 9.8 g in 100 g TOPICAL CREAM [I Conceal Flawless Foundation BS SPF 30 Sunscreen SUEDE]


name: Meradimate 3.5 mg in 100 mL / Octinoxate 7.5 mg in 100 mL / Oxybenzone 2 mg in 100 mL / Zinc Oxide 3 mg in 100 mL TOPICAL CREAM [Principal Secret Reclaim Sunscreen For Face and Body SPF 30]


name: OXYBENZONE 5 mg in 1 g / OCTISALATE 5 mg in 1 g / OCTINOXATE 7.5 mg in 1 g / OCTOCRYLENE 2.2 mg in 1 g TOPICAL EMULSION [CERAMIDE LIFT and FIRM]


name: Octinoxate 7.5 g in 100 g / Octisalate 5 g in 100 g / Zinc Oxide 3 g in 100 g TOPICAL CREAM [Principal Secret Reclaim Botanical (with SP) Radiant Recovery Day Broad Spectrum SPF 15]


name: HOMOSALATE 4.5 g in 50 mL / AVOBENZONE 1.35 g in 50 mL / OCTISALATE 2.25 g in 50 mL TOPICAL CREAM [ISNTREE HYALURONIC ACID DAILY SUNGEL]


name: HOMOSALATE 4.5 g in 50 mL / OCTINOXATE 3.4 g in 50 mL / OCTISALATE 2.25 g in 50 mL / OCTOCRYLENE 2 g in 50 mL / AVOBENZONE 1.35 g in 50 mL TOPICAL CREAM [ISNTREE ONION NEWPAIR SUNSCREEN]


name: TITANIUM DIOXIDE 90 mg in 1 mL / ZINC OXIDE 63 mg in 1 mL TOPICAL CREAM [it cosmetics Your Skin But Better CC Plus Color Correcting Broad Spectrum SPF 50 Plus Sunscreen Full Coverage Fair Ivory Fair Warm Fair Beige Medium Tan Warm Tan Rich Neutral Rich Neutral Deep Deep Bronze Deep Honey Deep Mocha]


name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 0.2 g TOPICAL STICK [Duke Sawtooth Antiperspirant]


name: AVOBENZONE 15 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 40 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [Neutrogena Invisible Daily Defense Broad Spectrum SPF 30]


name: OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL / HOMOSALATE 135 mg in 1 mL / OCTOCRYLENE 100 mg in 1 mL TOPICAL LOTION [Neutrogena Invisible Daily Defense Broad Spectrum SPF 60 Plus]


name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 0.2 g TOPICAL STICK [Duke Midnight Swim Antiperspirant]


name: ZINC OXIDE 180 mg in 1 mL TOPICAL CREAM [MIAMI BEACH BUM Save Face Sheer Mineral Sunscreen SPF 50]


name: HOMOSALATE 10 g in 100 g / OCTISALATE 5 g in 100 g / AVOBENZONE 2.5 g in 100 g TOPICAL STICK


name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 154 mg in 1 g TOPICAL STICK [DONNA KARAN CASHMERE MIST DEODORANT ANTI-PERSPIRANT]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 50 mg in 1 mL TOPICAL LIQUID [Caring mill Kids Sunscreen SPF 50]


name: OCTINOXATE 1.5 g in 30 g / TITANIUM DIOXIDE 0.51 g in 30 g TOPICAL CREAM [No7 Lift and Luminate Triple Action Serum Foundation Sunscreen Broad Spectrum SPF 15 Bamboo]


name: NIACINAMIDE 0.01 g in 100 mL TOPICAL GEL [Pugan vegan White Tomato formula Cleansing Gel]


name: SALICYLIC ACID 5 mg in 1 g TOPICAL POWDER [Neutrogena SkinClearing Mineral Powder Buff 30]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 70 mg in 1 mL / OCTISALATE 45 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL CREAM [REVITALIZING SUPREME YOUTH POWER Creme BROAD SPECTRUM SPF 25]


name: HOMOSALATE 4.25 g in 100 mL / OCTISALATE 4.75 g in 100 mL / ZINC OXIDE 6.75 g in 100 mL TOPICAL LIQUID [Always Liquid Foundation Makeup Sunscreen Broad Spectrum SPF 15 - Cocoa]


name: OCTISALATE 4.75 g in 100 mL / ZINC OXIDE 6.75 g in 100 mL / HOMOSALATE 4.25 g in 100 mL TOPICAL LIQUID [Always Liquid Foundation Makeup Sunscreen Broad Spectrum SPF 15 - Golden Tan]


name: OCTINOXATE 1.5 g in 30 g / TITANIUM DIOXIDE 0.51 g in 30 g TOPICAL CREAM [No7 Lift and Luminate Triple Action Serum Foundation Sunscreen Broad Spectrum SPF 15 Warm Ivory]


name: HOMOSALATE 4.25 g in 100 mL / OCTISALATE 4.75 g in 100 mL / ZINC OXIDE 6.75 g in 100 mL TOPICAL LIQUID [Always Liquid Foundation Makeup Sunscreen Broad Spectrum SPF 15 - Buff]


name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Bloomeffects Tulip Dew]


name: cefoperazone, sulbactam drug combination


name: cefepime, enmetazobactam drug combination


name: ENCEPHALITIS, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 12


name: ATRIAL FIBRILLATION 8, SUSCEPTIBILITY TO


name: FLCN, 2-BP DEL, 1284TC AND 1-BP INS, 1284A


name: TUBB1, 1-BP DEL, NT35 (dbSNP rs773248042)


name: HOXA13, 24-BP DUP, ALANINE TRACT EXPANSION


name: ACOX2, 4-BP DEL, 461TCTG (dbSNP rs34391522)


name: Vacuolar degeneration of spinous and granular layers


name: Decreased range of motion of palms and digits secondary to hyperkeratosis


name: Hemorrhagic diathesis (bleeding tendency)


name: Defect in stimulated platelet capacity to expose surface phosphatidylserine


name: Risk of life-threatening postpartum hemorrhage


name: Impaired intellectual development, moderate to severe (IQ 40 to 60)


name: Impaired intellectual development, mild, in most carrier females


name: Cerebellar hypoplasia (hemispheres and vermis affected equally)


name: Acrosomal Golgi apparatus absent or diffuse in round spermatids


name: Acrosomal granules ectopic, absent, or morphologically abnormal


name: Acrosomal vesicles too large or too small


name: Normal psychomotor development MISCELLANEOUS Females may be more mildly affected


name: Impaired induction of gamma-interferon production


name: Taurodontia (elongated body and short roots of mandibular molars)


name: Sensory or sensorimotor axonal peripheral neuropathy


name: Late potentials seen on signal-averaged ECG


name: Fibro-fatty infiltration seen on endomyocardial biopsy


name: Late potentials seen on electrocardiography (ECG)


name: Replacement of right ventricular myocardium with fatty tissue


name: Leukoencephalopathy Impaired intellectual development (mild)


name: Decreased or absent megakaryocytes on bone marrow biopsy


name: Hearing loss, progressive (conductive or mixed)


name: Fixation of the stapedial footplate in the oval window


name: Polymicrogyria (anterior to posterior gradient, most severe in the frontoparietal regions)


name: T2-weighted abnormalities in the basal ganglia and striatum


name: Difficulty adjusting to changes in luminance (bradyopsia)


name: Prolonged electroretinal response suppression time (PERRS)


name: Tapetoretinal degeneration around retinal arcades


name: Perivascular cuff of atrophic retinal pigment epithelium (RPE) surrounding superior and inferior arcades


name: Hypofluorescence in areas of RPE atrophy


name: Circular hyperfluorescence in parafoveal area


name: Thinning of outer plexiform layer seen on OCT


name: Thinning of outer nuclear layer seen on OCT


name: Loss of external limiting membrane seen on OCT


name: Early rod dysfunction seen on electroretinography


name: Later cone dysfunction seen on electroretinography


name: Myopathic and dystrophic changes seen on muscle biopsy


name: Anti-Sjogren syndrome type A (SSA) antibody positive


name: Anti-Ribonucleoprotein (RNP) antibody positive


name: Apnea in neonatal period requiring mechanical ventilation


name: Decreased plasma branched chain amino acids (leucine, isoleucine, valine)


name: Ventriculomegaly (in 1 patient) Polymicrogyria


name: Decreased activity of coupled complex activity in the electron transport chain seen on skeletal muscle biopsy


name: Poor feeding (requiring gastrostomy tube)


name: Worsening impaired intellectual development


name: Long palpebral fissures with lateral ectropion


name: Central macular atrophy surrounded by pigment clumping


name: Severe photoreceptor loss seen on optical coherence tomography


name: Extinguished responses to almost all stimuli seen on electroretinography


name: Sperm fail to activate oocyte (oocyte activation failure)


name: Swollen hepatocytes seen on liver biopsy


name: Meiotic arrest at zygotene or pachytene stage


name: Gross motor delay (walking after 18 months)


name: Sperm fail to activate oocyte (oocyte activation defect)


name: Decreased platelet aggregation in response to ADP, collagen, and epinephrine


name: Lesions in the basal ganglia seen on brain MRI


name: Hyperkeratosis (face, scalp, neck, trunk, extremities, Achilles tendon, dorsal surface of hands and feet)


name: Vacuolar degeneration of suprabasal keratinocytes


name: Amorphous keratin clumping in suprabasal layers


name: Abnormal diffuse signal in hemispheric white matter seen on MRI


name: Abnormal white matter with signal intensity close to/same as CSF (FLAIR images seen on MRI)


name: Elevated follicle-stimulating hormone (FSH) Decreased estrogen


name: Normal-mild developmental delay prior to disease onset


name: Symmetric and diffusely abnormal signal in cerebral hemispheric white matter seen on MRI


name: Abnormal white matter with signal intensity close to/same as CSF (T2-weighted or FLAIR images seen on MRI)


name: Intrauterine growth retardation (early-onset)


name: Elevated luteinizing hormone (late-onset)


name: Elevated follicle-stimulating hormone (late-onset)


name: Cystic degeneration of cerebral white matter seen on MRI


name: Thin glomerular basement membrane (seen on electron microscopy)


name: Absence of anti-IgA mesangial staining (seen on immunofluorescence)


name: Anti-Extractable nuclear antigen (ENA) positive


name: Myopathic features seen on EMG (involvement of the semitendinosus, biceps femoris, soleus, and gluteus maximus muscles)


name: Diffuse epidermolytic palmoplantar keratoderma


name: Hyperkeratosis seen on dorsal surface of fingers and toes, knees, elbows, axilla, and Achilles tendon


name: White spongy change of palms and soles following water exposure


name: Vacuolation of superficial keratinocytes


name: Decreased respiratory chain complex I and IV activity seen on muscle biopsy


name: T2-weighted abnormalities in the periventricular and deep white matter


name: Feeding difficulties due to oromotor dysfunction


name: Hypoplasia or agenesis of the vestibulocochlear nerve (CN VIII)


name: Increased numbers of smooth muscle fiber bundles in dermis


name: Impaired neutrophil superoxide production


name: Decreased or absent megakaryocytes in the bone marrow


name: Impulse control disorder while on dopamine agonists


name: Perivascular PAS-positive hyalin deposits in papillary and upper reticular dermis (present but less marked in unexposed skin)


name: Epidermal atrophy with necrotic keratinocytes


name: Perioral radial linear furrowing/scarring


name: Impaired platelet development from megakaryocytes


name: Perinuclear theca irregularly thickened and disorganized


name: Sperm unable to penetrate zona pellucida


name: Reduced megakaryocyte count in bone marrow


name: Reduced granulocytes seen on bone marrow biopsy


name: Polymicrogyria (frontal, perisylvian, or diffuse) on brain imaging


name: Pruritus, mild to moderate pruritus in cold dry weather


name: Whitish polygonal scales of face and extremities


name: Focal palmoplantar hyperkeratosis at birth


name: Diffuse palmoplantar keratoderma in childhood


name: Mild perivascular infiltration of monocytes in superficial dermis


name: Entombed lamellar bodies in stratum corneum


name: Bubble-like inclusions at the stratum granulosum-corneum interface


name: Increased corneodesmosomes in the upper stratum corneum


name: Mild valvular regurgitation (tricuspid, pulmonary, mitral)


name: Elevated lariat RNA in patient fibroblasts


name: Cloudy cornea No response to visual stimuli


name: Severely reduced right ventricular contraction


name: Persistent prolonged S wave in precordial leads seen on electrocardiography


name: Ventricular tachycardia (short runs or sustained)


name: Diffuse myocardial fibrosis (interstitial and replacement)


name: Length-dependent distal axonal motor neuropathy, lower limbs


name: Decreased compound muscle action potentials seen on electrophysiologic studies


name: Increased levels of Th2-related cytokines


name: Secondary bacterial, fungal, and viral skin infections


name: Defective granulopoiesis seen on bone marrow biopsy


name: Dystrophic granulocyte precursors and neutrophils


name: Simplified gyral pattern on brain imaging


name: Distal muscle weakness, lower limb predominant


name: Distal muscle atrophy, lower limb predominant


name: Denervation and reinnervation seen on EMG


name: Absent or hypoplastic distal interphalangeal creases


name: Abnormal glycosylation of serum transferrin


name: Failure of repair of double-stranded breaks


name: Incomplete assembly of synaptonemal complex


name: Failure of meiotic sex chromosome inactivation


name: Visual field defects, progressive (peripheral to central)


name: Retinal nerve fiber loss (severe, in all quadrants seen on optical coherence tomography)


name: Variable opacity of distal femoral metaphyses


name: Peripapillary telangiectatic (acute phase)


name: Thinning of retinal nerve fiber layer seen on OCT (chronic phase)


name: Hearing loss, progressive (conductive, sensorineural, or mixed)


name: Absent acoustic middle ear muscle reflexes seen on immittance testing


name: Reduction of nerve fiber layer thickness


name: Disproportionately prominent head of humerus


name: Disproportionately prominent medial and lateral epicondyles of humerus


name: Periarticular osteopenia at elbow joints


name: Periarticular osteopenia at joints of hands


name: Metaphyseal flaring of proximal middle phalanges


name: Periarticular regional osteopenia metatarsal heads


name: Periarticular regional osteopenia at base of phalanges


name: Sudden vision loss with subsequent recovery


name: Temporal retinal nerve fiber layer thinning


name: Reduced left ventricular ejection fraction, severe


name: Dilated left ventricle, moderate to severe


name: Mitral valve regurgitation, mild to moderate


name: Apical noncompaction of the left ventricle


name: Insulin resistance (in early adolescence)


name: Metaphyseal enlargement of proximal femur


name: Cortical bone erosion and new bone formation of femur


name: Cupping and irregular widening of metaphyses of lower limb bones


name: Abnormal appearance of basal ganglia seen on MRI


name: Increased serum creatine kinase Increased AST and ALT


name: Sensorineural deafness, severe bilateral


name: Structural brain abnormalities on brain imaging (variable)


name: Single interdigital crease of the thumb and fifth fingers


name: Prominent alveolar processes of maxilla and mandible


name: Irregular epiphyses of long tubular bones


name: Giant chondrocytes in epiphyseal plates of long bones


name: Thin long bone diaphyses with reduced medullary space


name: Joint hypermobility of wrists and fingers


name: Ulnar deviation at proximal interphalangeal joint (2/3)


name: Variable phalangeal hypoplasia or aplasia


name: Cupping of distal metacarpals and proximal end of proximal phalanges


name: Impaired secretion and response to gamma-interferon


name: 'Hot-cross bun' sign in the pontocerebellar region


name: 'Figure-of-eight' sign in the pontocerebellar region


name: 'Eye of the tiger sign' in the globus pallidus


name: Intracytoplasmic and intranuclear eosinophilic FTH1-positive inclusions in neurons throughout the brain seen on neuropathology


name: Transferrin saturation may be low or normal


name: Upper and lower respiratory tract infections


name: Impaired antibody response to polysaccharide vaccinations


name: Variable response to tetanus vaccination


name: Impaired differentiation of B cells into plasma cells


name: Decreased and nonfunctional plasma cells


name: Impaired B-cell and NK cell development seen on bone marrow biopsy


name: Loss of subcutaneous adipose tissue in the scalp seen on MRI


name: Accumulation of subcutaneous adipose tissue in the face


name: Loss of subcutaneous adipose tissue in the orbits seen on MRI


name: Accumulation of subcutaneous adipose tissue in the dorsal neck region


name: Accumulation of adipose tissue in the dorsal neck region


name: Accumulation of adipose tissue in the posterior cervicothoracic region


name: Accumulation of adipose tissue in the posterior intra-abdominal region


name: Loss of subcutaneous adipose tissue in the anterior truncal region


name: Loss of subcutaneous adipose tissue from the limbs


name: Abnormal accumulation of adipose tissue in the face and submental region


name: Dislocation of hip joints, complete or incomplete


name: Severely reduced progressive motility of spermatozoa


name: Hyperkeratosis (chest, arms, back, knees)


name: Vacuolar degeneration in suprabasal layer


name: Coarse keratohyaline granules in granular layer


name: Vacuolated electron-lucent cytoplasm in suprabasal layers


name: Coarse keratohyaline granules in suprabasal layer


name: Visual inattention (normalization by age 3 years)


name: Prominent perivascular spaces in the basal ganglia/pericaudate region


name: Prominent perivascular spaces adjacent to trigone of lateral ventricle


name: Acrosome small, incomplete, or structurally disordered


name: Scalloping of the cortical/white matter junction


name: Absence of glomerular basement membrane thickening or splitting (seen on electron microscopy)


name: Mucocutaneous bleeding (none or mild-to-moderate/severe)


name: DWI restriction abnormalities in the periventricular and deep white matter


name: Seizures (tonic-clonic, generalized myoclonic, absence, focal-onset)


name: Calcification of the globi pallidi, red nuclei, and substantia nigra


name: Systemic lupus erythematosus (SLE)/SLE-like disease


name: Confluent erythematous hyperkeratotic plaques on torso


name: Irregular layers of retina seen on transfoveal optical coherence tomography (OCT)


name: Absence of epidermal keratin 10 protein (immunohistology)


name: Kerecis omega3 marigen shield, per square centimeter (add-on, list separately in addition to primary procedure)


name: Neomatrix, per square centimeter (add-on, list separately in addition to primary procedure)


name: Innovaburn or innovamatrix xl, per square centimeter (add-on, list separately in addition to primary procedure)


name: Miro3d, per cubic centimeter (add-on, list separately in addition to primary procedure)


name: Accessories for patient inserted indwelling intraurethral drainage device with valve, replacement only, each


name: Monthly supplies for use of device coded at e0733


name: Neuromuscular electrical stimulator (nmes), disposable, replacement only


name: Gradient compression garment, glove, padded, for nighttime use, each


name: Gradient compression garment, glove, padded, for nighttime use, custom, each


name: Gradient compression garment, arm, padded, for nighttime use, each


name: Gradient compression garment, arm, padded, for nighttime use, custom, each


name: Gradient compression garment, lower leg and foot, padded, for nighttime use, each


name: Gradient compression garment, lower leg and foot, padded, for nighttime use, custom, each


name: Gradient compression garment, full leg and foot, padded, for nighttime use, each


name: Gradient compression garment, full leg and foot, padded, for nighttime use, custom, each


name: Gradient compression garment, bra, for nighttime use, each


name: Gradient compression garment, bra, for nighttime use, custom, each


name: Gradient compression stocking, below knee, 30-40 mmhg, used as a surgical dressing, each


name: Gradient compression stocking, below knee, 30-40 mmhg, custom, each


name: Gradient compression stocking, below knee, 40 mmhg or greater, each


name: Gradient compression stocking, below knee, 40 mmhg or greater, custom, each


name: Gradient compression stocking, thigh length, 18-30 mmhg, custom, each


name: Gradient compression stocking, thigh length, 30-40 mmhg, custom, each


name: Gradient compression stocking, thigh length, 40 mmhg or greater, custom, each


name: Gradient compression stocking, full length/chap style, 18-30 mmhg, custom, each


name: Gradient compression stocking, full length/chap style, 30-40 mmhg, custom, each


name: Gradient compression stocking, full length/chap style, 40 mmhg or greater, custom, each


name: Gradient compression stocking, waist length, 18-30 mmhg, custom, each


name: Gradient compression stocking, waist length, 30-40 mmhg, custom, each


name: Gradient compression stocking, waist length, 40 mmhg or greater, custom, each


name: Gradient compression gauntlet, custom, each


name: Gradient compression garment, neck/head, each


name: Gradient compression garment, neck/head, custom, each


name: Gradient compression garment, torso and shoulder, each


name: Gradient compression garment, torso/shoulder, custom, each


name: Gradient compression garment, genital region, each


name: Gradient compression garment, genital region, custom, each


name: Gradient compression garment, toe caps, each


name: Gradient compression garment, toe caps, custom, each


name: Gradient compression arm sleeve and glove combination, each


name: Gradient compression arm sleeve, custom, medium weight, each


name: Gradient compression arm sleeve, custom, heavy weight, each


name: Gradient compression glove, custom, medium weight, each


name: Gradient compression glove, custom, heavy weight, each


name: Gradient compression wrap with adjustable straps, below knee, each


name: Gradient compression wrap with adjustable straps, not otherwise specified


name: Gradient compression wrap with adjustable straps, above knee, each


name: Gradient compression wrap with adjustable straps, full leg, each


name: Gradient compression wrap with adjustable straps, foot, each


name: Gradient compression wrap with adjustable straps, arm, each


name: Gradient pressure wrap with adjustable straps, bra, each


name: External urinary catheters; disposable, with wicking material, for use with suction pump, per month


name: External urinary catheter; non-disposable, for use with suction pump, per month


name: Accessory for gradient compression garment or wrap with adjustable straps, not-otherwise specified


name: Gradient compression bandaging supply, bandage liner, lower extremity, any size or length, each


name: Gradient compression bandaging supply, bandage liner, upper extremity, any size or length, each


name: Gradient compression bandaging supply, conforming gauze, per linear yard, any width, each


name: Gradient compression bandage roll, elastic long stretch, linear yard, any width, each


name: Gradient compression bandage roll, elastic medium stretch, per linear yard, any width, each


name: Gradient compression bandage roll, inelastic short stretch, per linear yard, any width, each


name: Gradient compression bandaging supply, high density foam sheet, per 250 square centimeters, each


name: Gradient compression bandaging supply, high density foam pad, any size or shape, each


name: Gradient compression bandaging supply, high density foam roll for bandage, per linear yard, any width, each


name: Gradient compression bandaging supply, low density channel foam sheet, per 250 square centimeters, each


name: Gradient compression bandaging supply, low density flat foam sheet, per 250 square centimeters, each


name: Gradient compression bandaging supply, padded foam, per linear yard, any width, each


name: Gradient compression bandaging supply, padded textile, per linear yard, any width, each


name: Gradient compression bandaging supply, tubular protective absorption layer, per linear yard, any width, each


name: Gradient compression bandaging supply, tubular protective absorption padded layer, per linear yard, any width, each


name: Gradient compression bandaging supply, not otherwise specified


name: Gradient compression stocking, below knee, 18-30 mmhg, custom, each


name: Expiratory positive airway pressure intranasal resistance valve


name: Oral mucoadhesive, any type (liquid, gel, paste, etc.), per 1 ml


name: Programmer for transient, orally ingested capsule


name: Programable, transient, orally ingested capsule, for use with external programmer, per month


name: Prescription digital visual therapy, software-only, fda cleared, per course of treatment


name: Enteral feeding supply kit; elastomeric control fed, per day, includes but not limited to feeding/flushing syringe, administration set tubing, dressings, tape


name: Catheter, transluminal intravascular lesion preparation device, bladed, sheathed (insertable)


name: Endoscope, single-use (i.e. disposable), pulmonary, imaging/illumination device (insertable)


name: Orthopedic/device/drug matrix/absorbable bone void filler, antimicrobial-eluting (implantable)


name: Retrieval device, insertable, laser (used to retrieve intravascular inferior vena cava filter)


name: Bronchoscopy, rigid or flexible, with bronchial alveolar lavage and transendoscopic endobronchial ultrasound (ebus) during bronchoscopic diagnostic or therapeutic intervention(s) for peripheral lesion(s), including fluoroscopic guidance, when performed


name: Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed and intraprocedural coronary fractional flow reserve (ffr) with 3d functional mapping of color-coded ffr values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention


name: Endoscopic retrograde cholangiopancreatography (ercp) with removal of foreign body(s) or stent(s) from biliary/pancreatic duct(s) and endoscopic cannulation of papilla with direct visualization of pancreatic/common bile duct(s)


name: Group psychotherapy service for diagnosis, evaluation, or treatment of a mental health or substance use disorder provided remotely by hospital staff who are licensed to provide mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service


name: Endoscopic outlet reduction, gastric pouch application, with endoscopy and intraluminal tube insertion, if performed, including all system and tissue anchoring components


name: Instillation of anti-neoplastic pharmacologic/biologic agent into renal pelvis, any method, including all imaging guidance, including volumetric measurement if performed


name: Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant renal tissue, including imaging guidance


name: Magnetic resonance imaging with inhaled hyperpolarized xenon-129 contrast agent, chest, including preparation and administration of agent


name: Blinded or nonblinded procedure for symptomatic new york heart association (nyha) class ii, iii, iva heart failure; transcatheter implantation of left atrial to coronary sinus shunt using jugular vein access, including all imaging necessary to intra procedurally map the coronary sinus for optimal shunt placement (e.g., tee or ice ultrasound, fluoroscopy), performed under general anesthesia in an approved investigational device exemption (ide) study)


name: Therapeutic radiology simulation-aided field setting; complex, including acquisition of pet and ct imaging data required for radiopharmaceutical-directed radiation therapy treatment planning (i.e., modeling)


name: Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and real-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractions


name: Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by hardware remote


name: Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by hardware remote, 90-day supply


name: Non-pneumatic sequential compression garment, trunk


name: Upper extremity medical tubing/lines enclosure or covering device, restricts elbow range of motion


name: Virtual reality cognitive behavioral therapy device (cbt), including pre-programmed therapy software


name: Individual counseling for pre-exposure prophylaxis (prep) by physician or qualified health care professional (qhp) to prevent human immunodeficiency virus (hiv), includes hiv risk assessment (initial or continued assessment of risk), hiv risk reduction and medication adherence, 15-30 minutes


name: Injection of pre-exposure prophylaxis (prep) drug for hiv prevention, under skin or into muscle


name: Individual counseling for pre-exposure prophylaxis (prep) by clinical staff to prevent human immunodeficiency virus (hiv), includes: hiv risk assessment (initial or continued assessment of risk), hiv risk reduction and medication adherence


name: Psychotherapy for crisis furnished in an applicable site of service (any place of service at which the non-facility rate for psychotherapy for crisis services applies, other than the office setting); first 60 minutes


name: Psychotherapy for crisis furnished in an applicable site of service (any place of service at which the non-facility rate for psychotherapy for crisis services applies, other than the office setting); each additional 30 minutes (list separately in addition to code for primary service)


name: Community health integration services performed by certified or trained auxiliary personnel, including a community health worker, under the direction of a physician or other practitioner; 60 minutes per calendar month


name: Community health integration services, each additional 30 minutes per calendar month (list separately in addition to g0019)


name: Principal illness navigation services by certified or trained auxiliary personnel under the direction of a physician or other practitioner, including a patient navigator; 60 minutes per calendar month


name: Principal illness navigation services, additional 30 minutes per calendar month (list separately in addition to g0023)


name: Administration of a standardized, evidence-based assessment of physical activity and nutrition, 5-15 minutes, not more often than every 6 months


name: Intensive outpatient services; weekly bundle, minimum of 9 services over a 7 contiguous day period, which can include individual and group therapy with physicians or psychologists (or other mental health professionals to the extent authorized under state law); occupational therapy requiring the skills of a qualified occupational therapist; services of social workers, trained psychiatric nurses, and other staff trained to work with psychiatric patients; individualized activity therapies that are not primarily recreational or diversionary; family counseling (the primary purpose of which is treatment of the individual's condition); patient training and education (to the extent that training and educational activities are closely and clearly related to individual's care and treatment); diagnostic services; and such other items and services (excluding meals and transportation) that are reasonable and necessary for the diagnosis or active treatment of the individual's condition, reasonably expected to improve or maintain the individual's condition and functional level and to prevent relapse or hospitalization, and furnished pursuant to such guidelines relating to frequency and duration of services in accordance with a physician certification and plan of treatment (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure


name: Principal illness navigation - peer support by certified or trained auxiliary personnel under the direction of a physician or other practitioner, including a certified peer specialist; 60 minutes per calendar month, in the following activities: person-centered interview, performed to better understand the individual context of the serious, high-risk condition. ++ conducting a person-centered interview to understand the patient's life story, strengths, needs, goals, preferences, and desired outcomes, including understanding cultural and linguistic factors, and including unmet sdoh needs (that are not billed separately). ++ facilitating patient-driven goal setting and establishing an action plan. ++ providing tailored support as needed to accomplish the person-centered goals in the practitioner's treatment plan. identifying or referring patient (and caregiver or family, if applicable) to appropriate supportive services. practitioner, home, and community-based care communication. ++ assist the patient in communicating with their practitioners, home-, and community-based service providers, hospitals, and skilled nursing facilities (or other health care facilities) regarding the patient's psychosocial strengths and needs, goals, preferences, and desired outcomes, including cultural and linguistic factors. ++ facilitating access to community-based social services (e.g., housing, utilities, transportation, food assistance) as needed to address sdoh need(s). health education. helping the patient contextualize health education provided by the patient's treatment team with the patient's individual needs, goals, preferences, and sdoh need(s), and educating the patient (and caregiver if applicable) on how to best participate in medical decision-making. building patient self-advocacy skills, so that the patient can interact with members of the health care team and related community-based services (as needed), in ways that are more likely to promote personalized and effective treatment of their condition. developing and proposing strategies to help meet person-centered treatment goals and supporting the patient in using chosen strategies to reach person-centered treatment goals. facilitating and providing social and emotional support to help the patient cope with the condition, sdoh need(s), and adjust daily routines to better meet person-centered diagnosis and treatment goals. leverage knowledge of the serious, high-risk condition and/or lived experience when applicable to provide support, mentorship, or inspiration to meet treatment goals


name: Principal illness navigation - peer support, additional 30 minutes per calendar month (list separately in addition to g0140)


name: Iv thrombolytic therapy not initiated within 4.5 hours (<= 270 minutes) of time last known well for reasons documented by clinician (e.g. patient enrolled in clinical trial for stroke, patient admitted for elective carotid intervention)


name: Adherence to therapy was assessed at least annually through an objective informatics system or through self-reporting (if objective reporting is not available, documented)


name: Documentation of reason(s) for not objectively reporting adherence to evidence-based therapy (e.g., patients who have been diagnosed with a terminal or advanced disease with an expected life span of less than 6 months, patients who decline therapy, patients who do not return for follow-up at least annually, patients unable to access/afford therapy, patient's insurance will not cover therapy)


name: Adherence to therapy was not assessed at least annually through an objective informatics system or through self-reporting (if objective reporting is not available), reason not given


name: Documentation of medical reason(s) for not receiving hcv antibody test due to limited life expectancy


name: Behavioral counseling for diabetes prevention, in-person, group, 60 minutes


name: Behavioral counseling for diabetes prevention, distance learning, 60 minutes


name: Maintenance 5% wl from baseline weight in months 7-12


name: Coordinated specialty care, team-based, for first episode psychosis, per month


name: Coordinated specialty care, team-based, for first episode psychosis, per encounter


name: Molecular diagnostic test reader, nonprescription self-administered and self-collected use, fda approved, authorized or cleared


name: Supplies and accessories (e.g., transducer) for low frequency ultrasonic diathermy treatment device, per month


name: Hip orthosis, bilateral hip joints and thigh cuffs, adjustable flexion, extension, abduction control of hip joint, postoperative hip abduction type, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise


name: Addition to lower extremity prostheses, osseointegrated external prosthetic connector


name: Electrical stimulator supplies (external) for use with implantable neurostimulator, per month


name: Value in primary care mips value pathway


name: Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services


name: Administration of pneumococcal, influenza, hepatitis b, and/or covid-19 vaccine inside a patient's home; reported only once per individual home per date of service when such vaccine administration(s) are performed at the patient's home


name: Patient received at least two doses of the herpes zoster recombinant vaccine (at least 28 days apart) on october 20, 2017, through the end of the measurement period


name: No history of spirometry results with confirmed airflow obstruction (fev1/fvc < 70%) and present spirometry is >= 70%


name: Spirometry results with confirmed airflow obstruction (fev1/fvc < 70%) documented and reviewed


name: Documentation of medical reason(s) for not documenting and reviewing spirometry results (e.g., patients with dementia or tracheostomy)


name: No spirometry results with confirmed airflow obstruction (fev1/fvc < 70%) documented and/or no spirometry performed with results documented during the encounter


name: Documentation of system reason(s) for not documenting and reviewing spirometry results (e.g., spirometry equipment not available at the time of the encounter)


name: Patient has copd symptoms (e.g., dyspnea, cough/sputum, wheezing)


name: Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist or artificial intelligence (ai) interpretation documented and reviewed; with evidence of retinopathy


name: Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist or artificial intelligence (ai) interpretation documented and reviewed; without evidence of retinopathy


name: Glaucoma plan of care not documented, reason not otherwise specified


name: Intraocular pressure (iop) reduced by a value less than 20% from the pre-intervention level


name: Intraocular pressure (iop) reduced by a value of greater than or equal to 20% from the pre-intervention level


name: Iop measurement not documented, reason not otherwise specified


name: Patient, who has a reactive hcv antibody test, and has a follow up hcv viral test that detected hcv viremia, has hcv treatment initiated within 3 months of the reactive hcv antibody test


name: Patient, who has a reactive hcv antibody test, and has a follow up hcv viral test that detected hcv viremia, is referred within 1 month of the reactive hcv antibody test to a clinician who treats hcv infection


name: Patient has a reactive hcv antibody test and does not have a follow up hcv viral test, or patient has a reactive hcv antibody test and has a follow up hcv viral test that detects hcv viremia and is not referred to a clinician who treats hcv infection within 1 month and does not have hcv treatment initiated within 3 months of the reactive hcv antibody test, reason not given


name: Patient receives hcv antibody test with nonreactive result


name: Patient receives hcv antibody test with reactive result


name: Patient does not receive hcv antibody test or patient does receive hcv antibody test but results not documented, reason not given


name: Patient has a reactive hcv antibody test, and has a follow up hcv viral test that does not detect hcv viremia


name: Documentation or patient report of hcv antibody test or hcv rna test which occurred prior to the performance period


name: Patient reason for not screening for food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety (e.g., patient declined or other patient reasons)


name: Documentation that administration of second recombinant zoster vaccine could not occur during the performance period due to the recommended 2-6 month interval between doses (i.e, first dose received after october 31)


name: Patient did not respond to the question of patient felt heard and understood by this provider and team


name: Patient did not respond to the question of patient felt this provider and team put my best interests first when making recommendations about my care


name: Patient did not respond to the question of patient felt this provider and team saw me as a person, not just someone with a medical problem


name: Patient did not respond to the question of patient felt this provider and team understood what is important to me in my life


name: Patient provided a response other than "completely true" for the question of patient felt heard and understood by this provider and team


name: Patient provided a response other than "completely true" for the question of patient felt this provider and team put my best interests first when making recommendations about my care


name: Patient provided a response other than "completely true" for the question of patient felt this provider and team saw me as a person, not just someone with a medical problem


name: Patient provided a response other than "completely true" for the question of patient felt this provider and team understood what is important to me in my life


name: Patient responded "completely true" for the question of patient felt this provider and team put my best interests first when making recommendations about my care


name: Patient responded "completely true" for the question of patient felt this provider and team saw me as a person, not just someone with a medical problem


name: Patient responded "completely true" for the question of patient felt this provider and team understood what is important to me in my life


name: Patient responded as "completely true" for the question of patient felt heard and understood by this provider and team


name: Patients for whom a proxy completed the entire hu survey on their behalf for any reason (no patient involvement)


name: Patients who did not complete at least one of the four patient experience hu survey items and return the hu survey within 60 days of the ambulatory palliative care visit


name: Patients who respond on the patient experience hu survey that they did not receive care by the listed ambulatory palliative care provider in the last 60 days (disavowal)


name: Patients who were deceased when the hu survey reached them


name: Patients who have another reason for visiting the clinic [not prenatal or postpartum care] and have a positive pregnancy test but have not established the clinic as an ob provider (e.g., plan to terminate the pregnancy or seek prenatal services elsewhere)


name: Cvd risk assessment not performed or incomplete (e.g., cvd risk assessment was not documented), reason not otherwise specified


name: Cvd risk assessment performed, have a documented calculated risk score


name: Patients that were on the kidney or kidney-pancreas waitlist prior to initiation of dialysis


name: Patients who had a transplant prior to initiation of dialysis


name: Patients in hospice on their initiation of dialysis date or during the month of evaluation


name: Cms medical evidence form 2728 for dialysis patients: initial form completed


name: Patients admitted to a skilled nursing facility (snf)


name: Patients not observed in active status on any kidney or kidney-pancreas transplant waitlist as of the last day of each month during the measurement period


name: Patients observed in active status on any kidney or kidney-pancreas transplant waitlist as of the last day of each month during the measurement period


name: Receiving esrd mcp dialysis services by the provider on the last day of the reporting month


name: Patients not on any kidney or kidney-pancreas transplant waitlist as of the last day of each month during the measurement period


name: Patients with dementia at any time prior to or during the month


name: Patients observed on any kidney or kidney-pancreas transplant waitlist as of the last day of each month during the measurement period


name: Patients who were admitted to a skilled nursing facility (snf) within one year of dialysis initiation according to the cms-2728 form


name: Patients who were admitted to a skilled nursing facility (snf) during the month of evaluation were excluded from that month


name: Patients determined to be in hospice were excluded from month of evaluation and the remainder of reporting period


name: Colorectal cancer screening results were not documented and reviewed; reason not otherwise specified


name: Patients who are counseled on connection with a csp and explicitly opt out


name: Patients who did not have documented contact with a csp for at least one of their screened positive hrsns within 60 days after screening or documentation that there was no contact with a csp


name: Patients who had documented contact with a csp for at least one of their screened positive hrsns within 60 days after screening


name: Patients who screened positive for at least 1 of the 5 hrsns


name: Patients who were not seen within 7 weeks following the date of injection for follow up or who did not have a documented iop or no plan of care documented if the iop was >25 mm hg


name: Patients seen within 7 weeks following the date of injection and are screened for elevated intraocular pressure (iop) with tonometry with documented iop =<25 mm hg for injected eye


name: Patients seen within 7 weeks following the date of injection and are screened for elevated intraocular pressure (iop) with tonometry with documented iop >25 mm hg and a plan of care was documented


name: Patients who had an intravitreal or periocular corticosteroid injection (e.g., triamcinolone, preservative-free triamcinolone, dexamethasone, dexamethasone intravitreal implant, or fluocinolone intravitreal implant)


name: Patients who were not seen for reasons documented by clinician for patient or medical reasons (e.g., inadequate time for follow-up, patients who received a prior intravitreal or periocular steroid injection within the last six (6) months and had a subsequent iop evaluation with iop <25mm hg within seven (7) weeks of treatment)


name: Patients who were not appropriately evaluated during the initial exam and/or who were not re-evaluated within 8 weeks


name: Patients with a diagnosis of acute vitreous hemorrhage


name: Patients with a post-operative encounter of the eye with the acute pvd within 2 weeks before the initial encounter or 8 weeks after initial acute pvd encounter


name: Patients who were appropriately evaluated during the initial exam and were re-evaluated no later than 8 weeks from initial exam


name: Patients who were not appropriately evaluated during the initial exam and/or who were not re-evaluated within 2 weeks


name: Patients with a post-operative encounter of the eye with the acute pvd within 2 weeks before the initial encounter or 2 weeks after initial acute pvd encounter


name: Patients who were appropriately evaluated during the initial exam and were re-evaluated no later than 2 weeks


name: Patients who had follow-up assessment 30 to 180 days after the index assessment who did not demonstrate positive improvement or maintenance of functioning scores during the performance period


name: Patients who had follow-up assessment 30 to 180 days after the index assessment who demonstrated positive improvement or maintenance of functioning scores during the performance period


name: Index assessment completed using the 12-item whodas 2.0 or sds during the denominator identification period


name: Patients who did not have a follow-up assessment or did not have an assessment within 30 to 180 days after the index assessment during the performance period


name: Patients who died during the performance period (M1342)


name: Patients who are at pam level 4 at baseline or patients who are flagged with extreme straight line response sets on the pam or with excessive missing responses


name: Patients who had a completed suicide safety plan initiated, reviewed or updated in collaboration with their clinician (concurrent or within 24 hours) of the index clinical encounter


name: Patients who had a suicide safety plan initiated, reviewed, or updated and reviewed and updated in collaboration with the patient and their clinician concurrent or within 24 hours of clinical encounter and within 120 days after initiation


name: Suicidal ideation and/or behavior symptoms based on the c-ssrs or equivalent assessment


name: Patients who did not have a completed suicide safety plan initiated, reviewed or updated in collaboration with their clinician (concurrent or within 24 hours) of the index clinical encounter


name: Patients who did not have a suicide safety plan initiated, reviewed, or updated or reviewed and updated in collaboration with the patient and their clinician concurrent or within 24 hours of clinical encounter and within 120 days after initiation


name: Patients who had a reduction in suicidal ideation and/or behavior upon follow-up assessment within 120 days of index assessment


name: Patients who did not have a reduction in suicidal ideation and/or behavior upon follow-up assessment within 120 days of index assessment


name: Index assessment during the denominator period when the suicidal ideation and/or behavior symptoms or increased suicide risk by clinician determination occurs and a non-zero c-ssrs score is obtained


name: Suicidal ideation and/or behavior symptoms based on the c-ssrs


name: Patients who did not have a follow-up assessment within 120 days of the index assessment


name: Calculated 10-year ascvd risk score of >= 20 percent during the performance period


name: Patient encounter during the performance period with hospice and palliative care specialty code 17


name: Focusing on women's health mips value pathway


name: Quality care for the treatment of ear, nose, and throat disorders mips value pathway


name: Prevention and treatment of infectious disorders including hepatitis c and hiv mips value pathway


name: Quality care in mental health and substance use disorders mips value pathway


name: Rehabilitative support for musculoskeletal care mips value pathway


name: Amniobind or dermabind tl, per square centimeter (add-on, list separately in addition to primary procedure)


name: Neostim tl, per square centimeter (add-on, list separately in addition to primary procedure)


name: Neostim membrane, per square centimeter (add-on, list separately in addition to primary procedure)


name: Neostim dl, per square centimeter (add-on, list separately in addition to primary procedure)


name: Surgraft ft, per square centimeter (add-on, list separately in addition to primary procedure)


name: Complete sl, per square centimeter (add-on, list separately in addition to primary procedure)


name: Complete ft, per square centimeter (add-on, list separately in addition to primary procedure)


name: Esano a, per square centimeter (add-on, list separately in addition to primary procedure)


name: Esano aaa, per square centimeter (add-on, list separately in addition to primary procedure)


name: Esano ac, per square centimeter (add-on, list separately in addition to primary procedure)


name: Esano aca, per square centimeter (add-on, list separately in addition to primary procedure)


name: Orion, per square centimeter (add-on, list separately in addition to primary procedure)


name: Epieffect, per square centimeter (add-on, list separately in addition to primary procedure)


name: Vendaje ac, per square centimeter (add-on, list separately in addition to primary procedure)


name: Xcell amnio matrix, per square centimeter (add-on, list separately in addition to primary procedure)


name: Barrera sl or barrera dl, per square centimeter (add-on, list separately in addition to primary procedure)


name: Cygnus dual, per square centimeter (add-on, list separately in addition to primary procedure)


name: Biovance tri-layer or biovance 3l, per square centimeter (add-on, list separately in addition to primary procedure)


name: Dermabind sl, per square centimeter (add-on, list separately in addition to primary procedure)


name: Nudyn dl or nudyn dl mesh, per square centimeter (add-on, list separately in addition to primary procedure)


name: Nudyn sl or nudyn slw, per square centimeter (add-on, list separately in addition to primary procedure)


name: Dermabind dl, per square centimeter (add-on, list separately in addition to primary procedure)


name: Dermabind ch, per square centimeter (add-on, list separately in addition to primary procedure)


name: Revoshield + amniotic barrier, per square centimeter (add-on, list separately in addition to primary procedure)


name: Membrane wrap-hydro, per square centimeter (add-on, list separately in addition to primary procedure)


name: Lamellas xt, per square centimeter (add-on, list separately in addition to primary procedure)


name: Lamellas, per square centimeter (add-on, list separately in addition to primary procedure)


name: Acesso dl, per square centimeter (add-on, list separately in addition to primary procedure)


name: Amnio quad-core, per square centimeter (add-on, list separately in addition to primary procedure)


name: Amnio tri-core amniotic, per square centimeter (add-on, list separately in addition to primary procedure)


name: Rebound matrix, per square centimeter (add-on, list separately in addition to primary procedure)


name: Emerge matrix, per square centimeter (add-on, list separately in addition to primary procedure)


name: Amniocore pro, per square centimeter (add-on, list separately in addition to primary procedure)


name: Acesso tl, per square centimeter (add-on, list separately in addition to primary procedure)


name: Activate matrix, per square centimeter (add-on, list separately in addition to primary procedure)


name: Complete aca, per square centimeter (add-on, list separately in addition to primary procedure)


name: Complete aa, per square centimeter (add-on, list separately in addition to primary procedure)


name: Grafix plus, per square centimeter (add-on, list separately in addition to primary procedure)


name: Home injectable therapy, palivizumab or other monoclonal antibody for rsv, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem


name: Home injectable therapy, immunotherapy, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem


name: Graft, transmural transvenous arterial bypass (implantable), with all delivery system components


name: Amniocore pro+, per square centimeter (add-on, list separately in addition to primary procedure)


name: Surgraft xt, per square centimeter (add-on, list separately in addition to primary procedure)


name: Contact lens, hydrophilic, with blue-violet filter, per lens


name: Oncology (urothelial), mRNA expression profiling by real-time quantitative PCR of MDK, HOXA13, CDC2, IGFBP5, and CXCR2 in combination with droplet digital PCR (ddPCR) analysis of 6 single-nucleotide polymorphisms (SNPs) of genes TERT and FGFR3, urine, algorithm reported as a risk score for urothelial carcinoma


name: Oncology (colorectal) screening, quantitative real-time target and signal amplification of 8 RNA markers (GAPDH, SMAD4, ACY1, AREG, CDH1, KRAS, TNFRSF10B, EGLN2) and fecal hemoglobin, algorithm reported as a positive or negative for colorectal cancer risk


name: Oncology (pan-solid tumor), analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA, biomarker comparison to a previous baseline pre-treatment cell-free circulating DNA analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate


name: Psychiatry (eg, depression, anxiety), genomic analysis panel, including variant analysis of 26 genes, buccal swab, report including metabolizer status and risk of drug toxicity by condition


name: Oncology (prostate), exosome-based analysis of 53 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as no molecular evidence, low-, moderate-, or elevated-risk of prostate cancer


name: Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis, each comparator genome (eg, parents, siblings)


name: Human papillomavirus (HPV), oropharyngeal swab, 14 high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)


name: Gastroenterology, malabsorption evaluation of alpha-1-antitrypsin, calprotectin, pancreatic elastase and reducing substances, feces, quantitative


name: Glycine receptor alpha1 IgG, serum or cerebrospinal fluid (CSF), live cell-binding assay (LCBA), qualitative


name: Kelch-like protein 11 (KLHL11) antibody, serum or cerebrospinal fluid (CSF), cell-binding assay, qualitative


name: Oncology (prostate), 5 DNA regulatory markers by quantitative PCR, whole blood, algorithm, including prostate-specific antigen, reported as likelihood of cancer


name: Drug metabolism (adverse drug reactions and drug response), genomic analysis panel, variant analysis of 25 genes with reported phenotypes


name: Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on cytotoxicity percentage observed, minimum of 14 drugs or drug combinations


name: Oncology (lung), plasma analysis of 388 proteins, using aptamer-based proteomics technology, predictive algorithm reported as clinical benefit from immune checkpoint inhibitor therapy


name: Psychiatry (anxiety disorders), mRNA, gene expression profiling by RNA sequencing of 15 biomarkers, whole blood, algorithm reported as predictive risk score


name: Drug metabolism (adverse drug reactions and drug response), buccal specimen, gene-drug interactions, variant analysis of 33 genes, including deletion/duplication analysis of CYP2D6, including reported phenotypes and impacted gene-drug interactions


name: Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection, with counseling by physician or other qualified health care professional


name: Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection


name: CarePoint PRECISION 10mL Luer Lock Syringe without Needle


name: CarePoint PRECISION 20mL Luer Lock Syringe without Needle


name: CarePoint PRECISION 30mL Luer Lock Syringe without Needle


name: CarePoint PRECISION 3mL Luer Lock Syringe without Needle


name: CarePoint PRECISION 5mL Luer Lock Syringe without Needle


name: CarePoint PRECISION 60mL Luer Lock Syringe without Needle


name: CarePoint PRECISION 20G 1 inch Poly-Hub Hypodermic Needle


name: Contour Next Link 2.4 Blood Glucose Monitor System


name: Gold Bond Healing Hydration with Aloe Cream


name: CVS Mepilex Border Lite Foam Adhesive Dressing


name: Member's Mark BLULink Glucose Monitoring System


name: Member's Mark BLULink Glucose Test Strip


name: Member's Mark Blood Glucose Monitoring System


name: Unifine PROtect 4mm 32G 5/32 inch Pen Needle


name: Unifine PROtect 5mm 30G 3/16 inch Pen Needle


name: Unifine PROtect 8mm 30G 5/16 inch Pen Needle


name: Vagisil ProHydrate 24+Day Supply Long-Lasting Moisturizing Lubricant


name: Verifine Plus 4mm 32G 5/32 inch Pen Needle & Sharps Container


name: Vicks Speedread Thermometer Fever Insight


name: Vicks Super C Nyquil Liquicaps Nighttime Pack


name: Cleanser Topical application Soap [Daily Facial Cleanser]


name: Lotion, Multi Ingredient Topical application Lotion [Daily Ultra Moisture Lotion]


name: Milk/Whey Protein Isolate Oral Suspension [KetoVie 3:1]


name: ZINC OXIDE 22.5 g in 100 g TOPICAL STICK [Badger Broad Spectrum SPF 35 Active Face Stick]


name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Aspen Islanders Sheer Mineral Sport]


name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 160 mg in 1 g TOPICAL STICK [Papatui Antiperspirant Deodorant Cedar Sport]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 70 mg in 1 mL TOPICAL LOTION [La Roche Posay Laboratoire Dermatologique Anthelios 60 Face Light Fluid Sunscreen Broad Spectrum SPF 60 Water Resistant 80 Minutes]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 60 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 75 mg in 1 mL TOPICAL CREAM [YSE Beauty Skin Glow SPF 30 Primer]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 95 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 26 mg in 1 mL TOPICAL GEL [SEKKISEI HERBAL UV DEFENSE gel]


name: HOMOSALATE 73 mg in 1 mL / AVOBENZONE 30 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 90 mg in 1 mL TOPICAL STICK [HELLO SUNDAY THE ONE FOR YOUR LIPS CLEAR LIP BALM SPF 50]


name: OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 100 mg in 1 mL / HOMOSALATE 70 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL EMULSION [Hello Sunday The Everyday One Face Moisturiser SPF 50]


name: OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 90 mg in 1 mL / HOMOSALATE 70 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL EMULSION [Hello Sunday The One Thats a Serum Hydrating Serum SPF 45]


name: OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 90 mg in 1 mL / HOMOSALATE 73 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL EMULSION [Hello Sunday The Invisible One Sunscreen Plus Primer SPF 50]


name: OCTISALATE 50 mg in 1 mL / TITANIUM DIOXIDE 28 mg in 1 mL / ENSULIZOLE 30 mg in 1 mL TOPICAL CREAM [it cosmetics Your Skin But Better CC Plus Natural Matte Color Correcting Pore Refining Full Coverage Skin Balancing Serum Broad Spectrum SPF 40 Sunscreen]


name: ZINC OXIDE 20 g in 100 g TOPICAL STICK [ATTITUDE Sunly Mineral Sunscreen Stick Unscented SPF 30]


name: ZINC OXIDE 21 g in 100 mL TOPICAL CREAM [THE ENERGIST Multi-Defense Broad Spectrum Sunscreen SPF 50]


name: ZINC OXIDE 8 g in 50 mL TOPICAL LOTION [Innisfree Daily UV Defense Mineral Sunscreen]


name: ZINC OXIDE 175.2 mg in 1 mL TOPICAL EMULSION [Hello Sunday The Mineral One Lightweight Serum SPF 50]


name: ZINC OXIDE 217.3 mg in 1 g TOPICAL STICK [Hello Sunday The Shimmer One Mineral Glow SPF 45]


name: HOMOSALATE 4.25 g in 100 mL / OCTISALATE 4.75 g in 100 mL / ZINC OXIDE 6.75 g in 100 mL TOPICAL LIQUID [Always Liquid Foundation Makeup Sunscreen Broad Spectrum SPF 15 - Shell]


name: OCTISALATE 4.75 g in 100 mL / HOMOSALATE 4.25 g in 100 mL / ZINC OXIDE 6.75 g in 100 mL TOPICAL LIQUID [Always Liquid Foundation Makeup Sunscreen Broad Spectrum SPF 15 - Natural]


name: ZINC OXIDE 24.5 g in 100 g TOPICAL STICK [Botao - Grow Naturally Mineral Sunscreen Clear Facial Stick For Babies and Kids SPF 50]


name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 19 g in 100 g TOPICAL CREAM [Old Spice Sweat Defense Captain]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 150 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 70 mg in 1 mL TOPICAL LOTION [Equate Kids Sunscreen Broad Spectrum SPF 50 Equate]


name: TITANIUM DIOXIDE 1.52 g in 100 g / ZINC OXIDE 9.7 g in 100 g / OCTINOXATE 7 g in 100 g / OCTISALATE 3 g in 100 g TOPICAL CREAM [ELROEL Pang Pang Sun Cushion Plus]


name: ZINC OXIDE 15 g in 100 g TOPICAL CREAM [Elta MD UV AOX Eye]


name: OCTINOXATE 7.5 g in 100 mL / OCTISALATE 5 g in 100 mL TOPICAL LOTION [Vivant Day Treatment SPF 15]


name: AVOBENZONE 3 g in 100 g / HOMOSALATE 10 g in 100 g / OCTISALATE 5 g in 100 g / OCTOCRYLENE 10 g in 100 g TOPICAL STICK [Olay Glow plus Protect Sunscreen Dewy Glow SPF 50]


name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 9 g in 100 mL / OCTISALATE 4.5 g in 100 mL / OCTOCRYLENE 8.5 g in 100 mL TOPICAL LOTION [OLAY Prime plus Protect Facial Sunscreen with Vitamin C SPF35 Matte Finish]


name: HYDROQUINONE 2 g in 100 mL TOPICAL CREAM [Vivant True Tone]


name: HYDROQUINONE 2 g in 100 mL TOPICAL GEL [Vivant True Tone Forte]


name: ZINC OXIDE 15.52 g in 50 mL TOPICAL CREAM [THE FACE SHOP EVERYDAY MINERAL FACE PROTECTION SPF 50]


name: AVOBENZONE 3 g in 100 g / OCTISALATE 5 g in 100 g / HOMOSALATE 10 g in 100 g TOPICAL PASTE [SPF 25 LIP BALM]


name: AVOBENZONE 3 g in 100 mL / OCTOCRYLENE 6 g in 100 mL / HOMOSALATE 10 g in 100 mL TOPICAL LOTION [Death Tan SPF 50 Sport Sunscreen]


name: OCTINOXATE 75 mg in 1 mL / TITANIUM DIOXIDE 15 mg in 1 mL TOPICAL CREAM [REPAIRWEAR LASER FOCUS SPF 15 LINE SMOOTHING CO/O]


name: OCTOCRYLENE 2 g in 100 mL / OCTISALATE 5 g in 100 mL / ZINC OXIDE 8.4 g in 100 mL TOPICAL LOTION [Weightless Protection SPF 45]


name: Zinc Oxide 20 g in 100 mL TOPICAL CREAM [SHEER MINERAL SUNSCREEN]


name: Estrone 1 g in 1 g NOT APPLICABLE POWDER


name: AMINOCAPROIC ACID 1 g in 1 g NOT APPLICABLE POWDER [aminocaproid acid]


name: AVOBENZONE 2.2 g in 100 mL / HOMOSALATE 7 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL GEL [Multi Vitamin Clear Coat Broad Spectrum SPF 50]


name: TITANIUM DIOXIDE 60 mg in 1 g / HOMOSALATE 50 mg in 1 g / OCTISALATE 45 mg in 1 g / OCTOCRYLENE 30 mg in 1 g / ZINC OXIDE 63 mg in 1 g TOPICAL CREAM [e l f Camo Semi Matte CC SPF 30 Rich 620 W]


name: ZINC OXIDE 100 mg in 1 mL TOPICAL CREAM [e l f Sun Boss Gloss SPF 25 Sunscreen Its your Mauve]


name: ZINC OXIDE 63 mg in 1 g / TITANIUM DIOXIDE 60 mg in 1 g / HOMOSALATE 50 mg in 1 g / OCTISALATE 45 mg in 1 g / OCTOCRYLENE 30 mg in 1 g TOPICAL CREAM [e l f Camo Semi Matte CC SPF 30 Deep 530 W]


name: DIMETHICONE 12 h TOPICAL PATCH [RevivaSil]


name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 7 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 10 g in 100 mL TOPICAL CREAM [JAFRA SKIN Glow Face Cream Broad Spectrum SPF 15 Sunscreen]


name: RACTOPAMINE HYDROCHLORIDE 1 kg in 1 kg NOT APPLICABLE SUSPENSION


name: ZINC OXIDE 150 mg in 1 mL TOPICAL LIQUID [MIAMI BEACH BUM SPF-50 Blocked Sunscreen]


name: ZINC OXIDE 20 g in 100 g TOPICAL STICK [ATTITUDE Oatmeal Sensitive Natural Mineral Sunscreen Face Stick Unscented SPF 30]


name: OCTOCRYLENE 4 g in 50 mL / ZINC OXIDE 8.73 g in 50 mL / OCTISALATE 2.5 g in 50 mL / TITANIUM DIOXIDE 1.53 g in 50 mL TOPICAL CREAM [GANGNAM Glow Day Shield Perfect Sunscreen SPF 50]


name: OCTISALATE 4.5 g in 50 mL / HOMOSALATE 9 g in 50 mL / AVOBENZONE 2.7 g in 50 mL / OCTOCRYLENE 9 g in 50 mL TOPICAL CREAM [CNP Laboratory Sun Care Milky Light Sunscreen Broad Spectrum SPF 50]


name: POLYSILICONE-15 5 g in 100 g / OCTOCRYLENE 5 g in 100 g / OCTINOXATE 7 g in 100 g / HOMOSALATE 6 g in 100 g / AVOBENZONE 2 g in 100 g TOPICAL LIPSTICK [SUNSCREEN LIP BALM]


name: VITAMIN A 0.01 g in 100 g TOPICAL CLOTH [SKINEEZ]


name: ZINC OXIDE 10 g in 100 g TOPICAL STICK [ATTITUDE Sunly Lip balm Unscented SPF 15]


name: ASCORBIC ACID 10 mg in 100 mL TOPICAL LIQUID [Vitamin C 10 %]


name: ASCORBIC ACID 15 mg in 100 mL TOPICAL LIQUID [Vitamin C 15 %]


name: OCTINOXATE 1.995 g in 100 g TOPICAL POWDER [GOLDEN ROSE CORRECT AND CONCEAL Concealer Cream Palette]


name: HOMOSALATE 40 mg in 1 mL / OCTOCRYLENE 40 mg in 1 mL / OXYBENZONE 15 mg in 1 mL / TITANIUM DIOXIDE 103 mg in 1 mL TOPICAL CREAM [CLARINS UV PLUS ANTI-POLLUTION SUNSCREEN MULTI-PROTECTION BROAD SPECTRUM SPF 50 Oil-Free -DEEP]


name: FLURALANER 1 kg in 1 kg NOT APPLICABLE POWDER


name: eye drop administration aid MISCELL EACH


name: bitter mask flavor combination no.4 MISCELL POWDER (GRAM)


name: diluent for Haemophilus b vaccine (tetanus-conj)(0.9 % NaCl) 0.9 % INTRAMUSC SYRINGE (ML)


name: gelatin troche base no.265 MISCELL GEL (GRAM)


name: lactose-reduced food 0.07 gram-1.5 kcal/mL ORAL LIQUID (ML)


name: powder base no.266 MISCELL POWDER (GRAM)


name: sunflower/olive/beeswax/coconut/shea butter/marigold/argan TOPICAL OINTMENT (GRAM)


name: vehicle gel for anacaulase-bcdb TOPICAL GEL (GRAM)


name: CATHETER,SELF-CATH COUDE 16FR COLOPLAST #816


name: DRESSING,REINFORCED GELLING FIBERS + AG 18IN ROPE


name: HYALURONATE NA (BARRIGEL) 20MG/ML INJ,SYRINGE,3ML


name: DRESSING,ADAPTIC TOUCH NON-ADHERING SILICONE 8IN X 12.25IN


name: DRESSING,ADAPTIC TOUCH NON-ADHERING SILICONE 3IN X 4.25IN


name: BAG,ENTERAL DRAINAGE SET ENFIT #VED-012EO


name: STOMA CAPTURE CARTRIDGE STOMAGIENICS #12016


name: POUCH,DRAINABLE,HIGH OUTPUT FLEXTEND H#26064


name: CATHETER,SELF-CATH SOFT 12FR COLOPLAST #50181


name: CATHETER,SELF-CATH SOFT 14FR COLOPLAST #50182


name: CATHETER,SELF-CATH SOFT 16FR COLOPLAST #50183


name: DRESSING,MEDIHONEY HYDROGEL 4.3IN X 4.3IN


name: Provision of written information about cardiomyopathy


name: Provision of written information about prescribed diet


name: Provision of written information about breastfeeding


name: Provision of written information about weight management


name: Assessment using Asthma Therapy Assessment Questionnaire for children and adolescents


name: Assessment using Asthma Therapy Assessment Questionnaire Adult


name: Asthma Therapy Assessment Questionnaire Adult score


name: Asthma Therapy Assessment Questionnaire for children and adolescents score


name: Referral to transportation fuel voucher program


name: Assistance with application for transportation fuel voucher program


name: Evaluation of eligibility for transportation fuel voucher program


name: Education about transportation fuel voucher program


name: Provision of transportation fuel voucher


name: Assistance with application for child financial support


name: History of victim of elder psychological abuse


name: Suspected victim of elder psychological abuse


name: Evaluation of eligibility for Department of Veterans Affairs Veterans Benefits Program


name: Assistance with application for Department of Veterans Affairs Veterans Benefits Program


name: Education about transportation support program


name: Evaluation of eligibility for transportation support program


name: Referral to transportation support program


name: Assistance with application for residential abatement program


name: Assistance with application for socially assistive robots program


name: Assistance with application for Unemployment Insurance Program


name: Completed early-college high school program


name: Assistance with filing request for order of protection


name: Education about library educational programs


name: Education about National Immigration Law Center


name: Education about residential abatement program


name: Education about StrongHearts Native Helpline


name: Education about violence recovery program


name: Eligible for Department of Veterans Affairs National Cemetery Administration burial and memorial benefits


name: Evaluation of eligibility for Day Shelter Program


name: Evaluation of eligibility for residential abatement program


name: Provision of educational materials voucher


name: Referral to National Immigration Law Center


name: Referral to residential abatement program


name: Unable to obtain water in residence due to limited financial resources


name: Unable to obtain health insurance coverage due to limited financial resources


name: Hospital-based cardiac catheterization laboratory


name: Death associated with respiratory syncytial virus infection


name: Surveillance Epidemiology and End Results Program, Extent of Disease - 2018 edition


name: Provision of written information about smokeless tobacco cessation


name: Provision of written information about second hand smoke exposure


name: Provision of written information about nutrition while breast feeding


name: Provision of written information about nutrition


name: Provision of written information about natural family planning


name: Provision of written information about hypertension


name: Provision of written information about emergency contraception


name: Provision of written information about Dietary Approaches to Stop Hypertension


name: Provision of written information about contraception


name: Provision of written information about cholesterol management


name: Provision of written information about body mass index


name: Provision of written information about blood pressure measurement


name: Provision of written information about bariatric surgery


name: Provision of written information about alcohol withdrawal


name: Provision of written information about alcohol intoxication


name: Provision of written information about alcohol consumption


name: Provision of written information about alcohol abuse


name: Provision of pediatric asthma action plan


name: Provision of written information about preventing spread of disease caused by severe acute respiratory syndrome coronavirus 2


name: Provision of written information about disease caused by severe acute respiratory syndrome coronavirus 2


name: Victim of child abuse by parental intimate partner


name: Education toward completion of learning objectives of early-college high school program


name: Education toward completion of learning objectives of high school completion program


name: Education toward completion of learning objectives of General Educational Development Program


name: Kletsel Dehe Wintun Nation of the Cortina Rancheria, Tribal Entity


name: Oxalate & Glycolate & Glyoxylate & Citrate


name: SARS coronavirus 2 Mpro gene mutation detected


name: Coagulation surface induced.lupus sensitive.buffer (LA control)


name: Lupus anticoagulant aPTT screening panel


name: Cells.chromosome Y deletion/Cells counted


name: Cells.chromosome region 1p32 deletion/Cells counted


name: Cells.chromosome region 20q12 deletion/Cells counted


name: Hereditary motor neuropathy multigene analysis


name: Hereditary motor and sensory neuropathy multigene analysis


name: Hereditary sensory neuropathy multigene analysis


name: Hereditary spastic paraplegia multigene analysis


name: Hereditary congenital myasthenic syndrome multigene analysis


name: Hereditary emery dreifuss multigene analysis


name: Dyserythropoietic anemia multigene analysis


name: Erythrocytosis focused multigene analysis


name: CYB5 and CYB5 Reductase multigene analysis


name: EBV Lymphoproliferation multigene analysis


name: Dysregulation autoimmune multigene analysis


name: Autoimmune lymphoproliferative syndrome multigene analysis


name: Bacteria Identification and Susceptibility


name: Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Planned Discharge - version 5.1


name: Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Unplanned Discharge - version 5.1


name: Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Expired - version 5.1


name: Long-Term Care Hospital (LTCH) Continuity Assessment Record and Evaluation (CARE) Data Set (LCDS) - Admission - version 5.1


name: Peripheral neuropathy multigene analysis


name: Information to tell doctors if you have a sudden injury or illness with a good chance of recovery


name: Information to tell the medical team if you stop breathing or your heart stops beating


name: CMS - Inpatient Rehabilitation Facility - Patient Assessment Instrument - version 4.2


name: IRF-PAI v4.2, LCDS v5.1, MDS v1.19.1 - Functional abilities - admission


name: IRF-PAI v4.2, LCDS v5.1, MDS v1.19.1 - Functional abilities - discharge


name: Information to tell doctors if you experience failing health with a low chance of recovery


name: HISGT Histone genes targeted mutation analysis


name: Intensive Care Unit specialty destination


name: Multiple sulfatase deficiency enzymes panel


name: Basic metabolic & hemoglobin & hematocrit panel


name: Cosmetic facility registration-abbreviated renewal


name: Cosmetic facility registration-biennial renewal


name: Alive and without mechanical ventilation


name: Breast Cancer recurrence risk multigene analysis


name: Feeling down, depressed, irritable, or hopeless in last 2W


name: Poor appetite, weight loss, or overeating in last 2W


name: Trouble concentrating on things like school work, reading, or watching TV in last 2 weeks


name: Maternal condition that affected the fetus


name: Mucopolysaccharidosis type II newborn screen interpretation


name: Guanidinoacetate methyltransferase deficiency comment


name: Medication list for public health &or CDC reporting


name: Diagnostic multisection transesophageal & cardioversion panel


name: Multisection transesophageal for congenital disease


name: Views screening for diabetic retinopathy


name: Chronic and low grade B cell lymphoid neoplasm multigene analysis


name: B cell non hodgkin Lymphoma multigene analysis


name: Diagnostic peripheral vascular disease study


name: European tick borne encephalitis virus Ab.IgA index


name: Oxalate & Glycolate & Glyoxylate & Citrate:Imp:Pt:Urine:Nom


name: Escherichia coli O157:H7 DNA:PrThr:Pt:Wound:Ord:Probe.amp.tar


name: PLA2G7 & PLAC8 gene expression level:Score:Pt:Bld:Qn:Molgen


name: SARS coronavirus 2 Mpro gene mutation detected:Prid:Pt:XXX:Nom:Molgen


name: HIV 1 group O RNA+HIV 1 group M RNA+HIV 2 RNA+Hepatitis C virus RNA+Hepatitis B virus DNA+Hepatitis E virus RNA:PrThr:Pt:Ser/Plas/Bld^Donor:Ord:Probe.amp.tar


name: AAV serotype rh74 Ab:PrThr:Pt:Ser/Plas:Ord:IA


name: Direct antiglobulin test.polyspecific reagent:PrThr:Pt:RBC^Fetus:Ord


name: Staphylococcus aureus MLVA type:Type:Pt:Isolate/Specimen:Nom:Molgen


name: Imatinib ^24H post dose:MCnc:Pt:Ser/Plas:Qn:LC/MS/MS


name: N-Desethyl Sunitinib^24H post dose:MCnc:Pt:Ser/Plas:Qn:LC/MS/MS


name: Hepatitis B virus RNA:NCnc:Pt:Ser/Plas:Qn:Probe.amp.tar


name: Coagulation:Time:Pt:PPP:Qn:Coag.surface induced.lupus sensitive.buffer (LA control)


name: Lupus anticoagulant aPTT screening panel:-:Pt:PPP:-:Coag


name: Small lymphocytic lymphoma chromosome deletions &or rearrangements:Find:Pt:Bld/Tiss:Doc:FISH


name: Enterococcus faecalis+Enterococcus faecium DNA:PrThr:Pt:XXX:Ord:Probe.amp.tar


name: Klebsiella pneumoniae + Klebsiella oxytoca DNA:PrThr:Pt:XXX:Ord:Probe.amp.tar


name: Chlamydia trachomatis & Neisseria gonorrhoeae & Trichomonas vaginalis:PrThr:Pt:Genital fld:Ord:Probe.amp.tar


name: Coccidioides sp Ab.IgG & IgM:ACnc:Pt:Ser+CSF:Ord:IA


name: Herpes virus 6A DNA:NCnc:Pt:Ser/Plas:Qn:Non-probe.amp.tar


name: Herpes virus 6B DNA:ACnc:Pt:Ser/Plas:Qn:Non-probe.amp.tar


name: Cortisol^2H post dose corticotropin:MCnc:Pt:Ser/Plas:Qn


name: Lutropin^10M post dose gonadotropin releasing hormone:ACnc:Pt:Ser/Plas:Qn


name: Lutropin^4H post dose gonadotropin releasing hormone:ACnc:Pt:Ser/Plas:Qn


name: Cells.chromosome Y deletion/Cells counted:NFr:Pt:Bld/Bone mar:Qn:FISH


name: Campylobacter & Salmonella & Shigella sp:Prid:Pt:Stool:Nom:Organism specific culture


name: Campylobacter & Salmonella & Shigella & Yersinia sp:Prid:Pt:Stool:Nom:Organism specific culture


name: Salmonella & Shigella & Campylobacter & E. coli sp:Prid:Pt:Stool:Nom:Organism specific culture


name: Cells.chromosome region 1p32 deletion/Cells counted:NFr:Pt:Bld/Bone mar:Qn:FISH


name: Cells.chromosome region 1q21 duplication:NFr:Pt:Bld/Bone mar:Qn:FISH


name: Soluble triggering receptor expressed on myeloid cells-1:MCnc:Pt:Ser/Plas:Qn:IA


name: Hemiplegic migraine multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: CTNNB1 gene targeted mutation analysis:Find:Pt:Tumor:Doc:Molgen


name: TP53 gene full mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Gamma aminobutyrate A receptor Ab.IgG:PrThr:Pt:CSF:Ord:CBA IFA


name: Deprecated Yersinia pestis DNA [Presence] in Blood by NAA with non-probe detection


name: Crimean-Congo hemorrhagic fever virus RNA:PrThr:Pt:Bld:Ord:Non-probe.amp.tar


name: Ebolavirus Bundibugyo+Reston+Sudan+Taï Forest+Zaire RNA:PrThr:Pt:Bld:Ord:Non-probe.amp.tar


name: West Nile virus RNA:PrThr:Pt:Bld:Ord:Non-probe.amp.tar


name: Yellow fever virus RNA:PrThr:Pt:Bld:Ord:Non-probe.amp.tar


name: Cells.chromosome region 20q12 deletion/Cells counted:NFr:Pt:Bld/Bone mar:Qn:FISH


name: Hereditary motor neuropathy multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Hereditary motor and sensory neuropathy multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Hereditary sensory neuropathy multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Hereditary spastic paraplegia multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Distal weakness multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Hereditary congenital myasthenic syndrome multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Hereditary emery dreifuss multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Dyserythropoietic anemia multigene analysis:Find:Pt:XXX:Doc:Sequencing


name: CYB5 and CYB5 Reductase multigene analysis:Find:Pt:XXX:Doc:Sequencing


name: RBC membrane multigene analysis:Find:Pt:XXX:Doc:Sequencing


name: EBV Lymphoproliferation multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Hyper igE syndrome multigene analysis:Find:Pt:XXX:Doc:Molgen


name: Dysregulation autoimmune multigene analysis:Find:Pt:XXX:Doc:Molgen


name: Viral Susceptibility multigene analysis:Find:Pt:XXX:Doc:Molgen


name: Autoimmune lymphoproliferative syndrome multigene analysis:Find:Pt:XXX:Doc:Molgen


name: Human papilloma virus 16 & 18+45 mRNA:PrThr:Pt:Anorectal:Ord:Probe.amp.tar


name: Chemokine (C-C motif) ligand 26:MCnc:Pt:Ser/Plas:Qn:IA


name: Monocyte Chemoattractant Proteins 4:MCnc:Pt:Ser/Plas:Qn:IA


name: Influenza A H3N2V RNA:PrThr:Pt:XXX:Ord:Probe.amp.tar


name: Bacteria Identification and Susceptibility:Find:Pt:Bld.pos growth:Doc


name: Aeromonas & plesiomonas sp:Prid:Pt:Stool:Nom:Organism specific culture


name: Renal calculus risk assessment:Likelihood:24H:Urine:Nar


name: Tripartite motif containing 46:PrThr:Pt:XXX:Ord:IF


name: HBA1 & HBA2 gene deletion:Find:Pt:Amnio fld/CVS:Doc:Molgen


name: NOTCH3 gene full mutation analysis:Find:Pt:XXX:Doc:Molgen


name: Motor neuron disease multigene analysis:Find:Pt:XXX:Doc:Molgen


name: Muscular dystrophy multigene analysis:Find:Pt:XXX:Doc:Molgen


name: HIF2A gene targeted mutation analysis:Find:Pt:Bld:Doc:Molgen


name: Peripheral neuropathy multigene analysis:Find:Pt:XXX:Doc:Molgen


name: KRAS Somatic mutation analysis:Find:Pt:Tumor:Doc:Molgen


name: Parkinson Disease multigene analysis:Find:Pt:XXX:Doc:Molgen


name: HISGT Histone genes targeted mutation analysis:Find:Pt:Tumor:Doc:Molgen


name: Multiple sulfatase deficiency enzymes panel:-:Pt:WBC:-


name: Basic metabolic & hemoglobin & hematocrit panel:-:Pt:Bld:-


name: Human bocavirus DNA:PrThr:Pt:Respiratory system specimen.upper:Ord:Non-probe.amp.tar


name: Legionella pneumophila DNA:PrThr:Pt:Respiratory system specimen.upper:Ord:Non-probe.amp.tar


name: Cells.CD34 recipient derived/Cells.CD34^post stem cell transplantation:NFr:Pt:Bone mar:Qn:Molgen


name: Breast Cancer recurrence risk multigene analysis:Find:Pt:Tiss:Doc:Molgen


name: Cytokeratin 19 mRNA for cancer metastasis:PrThr:Pt:Lymph node:Ord:Non-probe.amp.tar


name: TRCA+TCRD gene rearrangements:Find:Pt:Bone mar:Doc:FISH


name: TCL-1A gene rearrangements:Find:Pt:Bone mar:Doc:FISH


name: Human papilloma virus 31+33+52+58 DNA:PrThr:Pt:Cvx:Ord:Probe.amp.tar


name: Clostridium tetani toxin TeNT gene:PrThr:Pt:XXX:Ord:Non-probe.amp.tar


name: Clostridium tetani toxin TeNT gene:PrThr:Pt:XXX:Ord:Probe.amp.tar


name: Clostridium tetani toxin:PrThr:Pt:XXX:Ord:Mouse bioassay.neutralization


name: Clostridium tetani toxin:PrThr:Pt:XXX:Ord:Endopeptidase Assay


name: Clostridium tetani toxin:PrThr:Pt:Ser/Plas:Ord:Endopeptidase Assay


name: Clostridium tetani toxin:PrThr:Pt:Ser/Plas:Ord:Mouse bioassay


name: Mucopolysaccharidosis type II newborn screen interpretation:Imp:Pt:Bld.dot:Nom


name: Mucopolysaccharidosis type II comment:Txt:Pt:Bld.dot:Nar


name: Guanidinoacetate methyltransferase deficiency comment:Txt:Pt:Bld.dot:Nar


name: Immunoglobulin lambda light chain gene 22q11.22 rearrangement:Find:Pt:XXX:Doc:FISH


name: Immunoglobulin kappa light chain gene 2p11.2 rearrangement:Find:Pt:XXX:Doc:FISH


name: CRLF2 gene rearrangements:Find:Pt:Bld/Bone mar:Doc:FISH


name: Chronic and low grade B cell lymphoid neoplasm multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: B cell non hodgkin Lymphoma multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Histiocytic neoplasm multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: Plasma cell myeloma multigene analysis:Find:Pt:Bone mar:Doc:Molgen


name: T cell lymphoma multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen